Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study
NCT ID: NCT07291817
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-11-03
2026-11-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will have baseline assessments (i.e. toe pressure measurement and wound area measurement) performed on them and training on the use of FlowOx device will be provided to them in Visit 1. Participants will be tasked to use the FlowOx device (device will be loaned to them) for 1 hour twice daily. A phone call will be conducted 1 week after Visit 1 to follow up on the medical and user-related issues. At Week 6 (Visit 2), participants will be asked to come back for toe pressure and wound area measurement. At Week 12 (Visit 3), end of treatment assessments (i.e toe pressure and wound area measurement) will be performed. Compliance data will be acquired from the FlowOx device.
Their participation in the study will last for 12 weeks. Participants will be asked to use the FlowOx device for one hour, two times a day throughout the study period. They will need to visit the clinic 3 times in the course of the study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment with FlowOx
FlowOx
12 weeks treatment with FlowOx for 1 hour twice daily for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FlowOx
12 weeks treatment with FlowOx for 1 hour twice daily for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male or female, aged 21-99.
4. Diagnosed with diabetes mellitus.
5. Toe systolic pressure \<70 mmHg on the leg to be treated (after revascularization)
6. Open chronic wound on the foot
7. Ability to operate the treatment device, and willing to adhere to the study intervention regimen.
8. Suitable for diabetic limb salvage
Exclusion Criteria
2. Treatment with another investigational intervention within the last 12 weeks prior to inclusion.
3. Pregnant women or cognitively impaired participants.
21 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otivio AS
INDUSTRY
Lo Zhiwen Joseph
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lo Zhiwen Joseph
Senior Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhiwen Joseph Lo
Role: PRINCIPAL_INVESTIGATOR
Woodlands Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Woodlands Health
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhiwen Joseph Lo
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Yagshyyev S, Hausmann P, Li Y, Kempf J, Zetzmann K, Dessi K, Moosmann O, Almasi-Sperling V, Meyer A, Gerken ALH, Lang W, Rother U. Intermittent negative pressure therapy in patients with no-option chronic limb-threatening ischemia. Vasa. 2023 Nov;52(6):402-408. doi: 10.1024/0301-1526/a001098. Epub 2023 Oct 17.
Herrmann LG, Reid MR. THE CONSERVATIVE TREATMENT OF ARTERIOSCLEROTIC PERIPHERAL VASCULAR DISEASES: PASSIVE VASCULAR EXERCISES (PAVAEX THERAPY). Ann Surg. 1934 Oct;100(4):750-60. doi: 10.1097/00000658-193410000-00016. No abstract available.
Landis E.M HLH. The clinical value of alternate suction and pressure in the treatment of advanced peripheral vascular disease. The American Journal of the Medical Sciences. 1935;189(3):20.
Sinkowitz S, Gottlieb I. Thrombo-angiitis obliterans the conservative treatment by Bier's hyperemia suction apparatus. JAMA.1917;LXVIII(13):961-963.
Sundby OH, Hoiseth LO, Mathiesen I, Jorgensen JJ, Sundhagen JO, Hisdal J. The effects of intermittent negative pressure on the lower extremities' peripheral circulation and wound healing in four patients with lower limb ischemia and hard-to-heal leg ulcers: a case report. Physiol Rep. 2016 Oct;4(20):e12998. doi: 10.14814/phy2.12998.
Sundby OH, Irgens I, Hoiseth LO, Mathiesen I, Lundgaard E, Haugland H, Weedon-Fekjaer H, Sundhagen JO, Sandbaek G, Hisdal J. Intermittent mild negative pressure applied to the lower limb in patients with spinal cord injury and chronic lower limb ulcers: a crossover pilot study. Spinal Cord. 2018 Apr;56(4):372-381. doi: 10.1038/s41393-018-0080-4. Epub 2018 Mar 1.
Hoel H, Pettersen EM, Hoiseth LO, Mathiesen I, Seternes A, Hisdal J. A randomized controlled trial of treatment with intermittent negative pressure for intermittent claudication. J Vasc Surg. 2021 May;73(5):1750-1758.e1. doi: 10.1016/j.jvs.2020.10.024. Epub 2020 Oct 22.
Sundby OH, Hoiseth LO, Mathiesen I, Weedon-Fekjaer H, Sundhagen JO, Hisdal J. The acute effects of lower limb intermittent negative pressure on foot macro- and microcirculation in patients with peripheral arterial disease. PLoS One. 2017 Jun 7;12(6):e0179001. doi: 10.1371/journal.pone.0179001. eCollection 2017.
Hoel H, Hoiseth LO, Sandbaek G, Sundhagen JO, Mathiesen I, Hisdal J. The acute effects of different levels of intermittent negative pressure on peripheral circulation in patients with peripheral artery disease. Physiol Rep. 2019 Oct;7(20):e14241. doi: 10.14814/phy2.14241.
Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, van Baal J, van Merode F, Schaper N. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007 Jan;50(1):18-25. doi: 10.1007/s00125-006-0491-1. Epub 2006 Nov 9.
Petersen BJ, Linde-Zwirble WT, Tan TW, Rothenberg GM, Salgado SJ, Bloom JD, Armstrong DG. Higher rates of all-cause mortality and resource utilization during episodes-of-care for diabetic foot ulceration. Diabetes Res Clin Pract. 2022 Feb;184:109182. doi: 10.1016/j.diabres.2021.109182. Epub 2022 Jan 18.
Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017 Jun 15;376(24):2367-2375. doi: 10.1056/NEJMra1615439. No abstract available.
Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global Disability Burdens of Diabetes-Related Lower-Extremity Complications in 1990 and 2016. Diabetes Care. 2020 May;43(5):964-974. doi: 10.2337/dc19-1614. Epub 2020 Mar 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-4641
Identifier Type: -
Identifier Source: org_study_id